Topic Editors

Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, Bucharest, Romania
1. Department II, University of Medicine and Pharmacy "Carol Davila" Bucharest, 020021 Bucharest, Romania
2. Department of Surgery 3, “Prof. Dr. Al. Trestioreanu” Institute of Oncology, 022338 Bucharest, Romania
Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, 061071 Bucharest, Romania

From Basic Research to a Clinical Perspective in Oncology

Abstract submission deadline
30 September 2024
Manuscript submission deadline
31 December 2024
Viewed by
986

Topic Information

Dear Colleagues,

We are happy to open this Topic in cooperation with the OncoHub Conference and share the aim of creating a proper space where interdisciplinary teams of biomedical researchers could share their latest scientific advances and bring together the cancer research medical communities to inspire innovation and build knowledge, networks, and collaborations. Our main focus is on bridging the gap between clinical research, clinicians, and industry by identifying promising tools for drug discovery and targets for novel therapies. For this, we encourage the submission of any original work or review manuscript that could inspire other professionals to gain insight into the clinical relevance of molecular diagnostic advances, circulating markers for liquid biopsy development, disease modeling in bioprinted microfluidic devices, modern endoscopic and/or surgical techniques in different cancer types, etc.

Dr. Bianca Gǎlǎţeanu
Dr. Octav Ginghină
Dr. Ariana Hudita
Topic Editors

Keywords

  • liquid biopsy
  • tumor microenvironment
  • immuno-oncology
  • sentinel lymph node mapping
  • radiofrequency ablation

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cancers
cancers
5.2 7.4 2009 18.2 Days CHF 2900 Submit
Diagnostics
diagnostics
3.6 3.6 2011 18.8 Days CHF 2600 Submit
Journal of Clinical Medicine
jcm
3.9 5.4 2012 19.7 Days CHF 2600 Submit
Pharmaceutics
pharmaceutics
5.4 6.9 2009 17 Days CHF 2900 Submit
Current Oncology
curroncol
2.6 2.6 1994 18.4 Days CHF 2200 Submit

Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.

Published Papers (1 paper)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
14 pages, 1549 KiB  
Article
Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
Curr. Oncol. 2023, 30(11), 10019-10032; https://doi.org/10.3390/curroncol30110728 - 19 Nov 2023
Viewed by 627
Abstract
(1) Background: BRAF mutations affect 4–5% of lung adenocarcinomas. This study aimed to analyze the clinicopathological features of lung carcinomas with BRAF mutations, focusing on V600E vs. non-V600E and the presence of co-mutations. (2) Methods: All BRAF-mutated lung carcinomas were retrieved from a [...] Read more.
(1) Background: BRAF mutations affect 4–5% of lung adenocarcinomas. This study aimed to analyze the clinicopathological features of lung carcinomas with BRAF mutations, focusing on V600E vs. non-V600E and the presence of co-mutations. (2) Methods: All BRAF-mutated lung carcinomas were retrieved from a molecular diagnostic unit (the reference unit for four different hospitals). The samples were analyzed using next-generation sequencing. Statistical analyses included log-rank tests for overall survival (OS) and progression-free survival (PFS). (3) Results: In total, 60 BRAF-mutated lung carcinomas were retrieved: 24 (40.0%) with V600E and 36 (60.0%) with non-V600E mutations, and 21 (35.0%) with other co-mutations and 39 (65.0%) with only BRAF mutations. Survival data were available for 54/60 (90.0%) cases. Targeted therapy was documented in 11 cases. Patients with V600E mutations exhibited a better prognosis than patients with non-V600E mutations (p = 0.008 for OS, p = 0.018 for PFS); this was confirmed in PFS (p = 0.036) when considering only patients who received no targeted therapy. Patients with co-mutations displayed no prognostic difference compared to patients carrying only BRAF mutations (p = 0.590 for OS, p = 0.938 for PFS). (4) Conclusions: BRAF-mutated lung carcinomas with V600E (40.0%) had a better prognosis than those without V600E. Concomitant co-mutations (35.0%) did not affect the prognosis. Full article
(This article belongs to the Topic From Basic Research to a Clinical Perspective in Oncology)
Show Figures

Graphical abstract

Back to TopTop